RESUMEN
The analytical performance of the tumour markers CA 15-3 assay, CA 19-9 assay and Ca 125 II assay on the Bayer Immuno I System was studied according to a revised version of the ECCLS guidelines (Haeckel R. In: Evaluation methods in laboratory medicine, Weinheim, VCH Verlag 1993:47-69) in a multicentre evaluation involving five laboratories. Determination of the 3 analytes generated more than 6000 data. On the Bayer Immuno I System, the imprecisions of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay were better than those found for comparison methods. The median recovery over all five laboratories of system assigned values in control sera was within the 1-s range for the three tumour marker assays. No deviation of linearity could be detected experimentally for all assays. Results for patients' samples showed acceptable agreement between the Bayer Immuno 1 system and several different comparison methods in most cases. One exception was the CA 15-3 assay in comparison with the MCA assay from Roche Diagnostic Systems, where the large difference in values is due to the use of different antibodies and calibrators in the two assays. No carry-over effects could be detected. The selective Bayer Immuno 1 system is fully automated; its practicability was rated as high.
Asunto(s)
Antígenos de Carbohidratos Asociados a Tumores/sangre , Biomarcadores de Tumor/sangre , Inmunoensayo/métodos , Antígenos de Carbohidratos Asociados a Tumores/inmunología , Biomarcadores de Tumor/inmunología , Biomarcadores de Tumor/normas , Antígeno Ca-125/sangre , Antígeno Ca-125/inmunología , Antígeno CA-19-9/sangre , Antígeno CA-19-9/inmunología , Humanos , Inmunoensayo/normas , Modelos Lineales , Mucina-1/sangre , Mucina-1/inmunología , Control de Calidad , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
Using clinical and biochemical data, the efficacy of the topical application of kontrikal, a polyfunctional inhibitor of proteinases, for the therapy of chronic purulent sinusitis is discussed. The drug was found to reduce the activity of proteolytic enzymes in the purulent exudate from the maxillary sinus. As compared with the controls (27 patients), the treated group (38 patients) showed a rapid disappearance of clinical manifestations, shortening of the therapeutic period, increase of proteinase inhibitors and decrease of protein in the exudate.
Asunto(s)
Aprotinina/uso terapéutico , Sinusitis Maxilar/tratamiento farmacológico , Inhibidores de Proteasas/uso terapéutico , Adolescente , Adulto , Enfermedad Crónica , Humanos , Persona de Mediana Edad , SupuraciónRESUMEN
Specific proteolytic and antitryptic activities were measured in the sinus exudate of 27 patients with chronic suppurative maxillary sinusitis. Most patients showed a shift in the proteinase-inhibitor system with proteolytic activity being predominant. In the course of treatment antitryptic activity in the exudate increased. It was found that biochemical data were correlated with clinical manifestations. It is concluded that patients with the above pathology should be prescribed proteolytic enzymes on an individual basis and that natural proteinase inhibitors should be included into the combined therapy.
Asunto(s)
Exudados y Transudados/enzimología , Seno Maxilar/enzimología , Sinusitis Maxilar/enzimología , Péptido Hidrolasas/análisis , Inhibidores de Proteasas/análisis , Adolescente , Adulto , Femenino , Humanos , Masculino , Sinusitis Maxilar/tratamiento farmacológico , Persona de Mediana Edad , Péptido Hidrolasas/uso terapéutico , Inhibidores de Proteasas/uso terapéutico , Inhibidores de Tripsina/análisis , Inhibidores de Tripsina/uso terapéuticoRESUMEN
Human blood plasma inhibitors are studied for their effect on the activity of terrilytin, a proteolytic enzyme of microbial origin, and terridecase, its immobilized form. The main plasma inhibitor of terrilytin is alpha 2-macroglobulin (alpha 2 MG). The pattern of terrilytin and terridecase interaction with alpha 2 MG preparation isolated from human blood plasma has also been studied. The inhibitor is found to exert a slight retarding effect on the terridecase activity. Significant differences in alpha 2 MG inactivation of terrilytin and trypsin are observed.